Entrada Therapeutics (TRDA) Set to Announce Quarterly Earnings on Thursday

Key Points

• Entrada Therapeutics is expected to report Q3 2026 results before market open on November 5, with analysts forecasting a loss of $0.98 per share and revenue of $2.13 million. The earnings call is scheduled for November 6 at 9:30 a.m. ET.
• The company’s previous quarter fell short of expectations, posting a $1.01-per-share loss and $0.90 million in revenue versus estimates of a $0.97 loss and $2.32 million in revenue.
• TRDA shares have declined significantly, opening at $4.84 compared with a 52-week high of $16.45. The stock carries a consensus “Hold” rating and a $17.75 average analyst price target, while insiders have sold more than 717,000 shares over the past 90 days.

Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) is anticipated to issue its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Entrada Therapeutics to post earnings of ($0.98) per share and revenue of $2.13 million for the quarter. Individuals may review the information on the company's upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Friday, November 6, 2026 at 9:30 AM ET.

Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($1.01) earnings per share for the quarter, missing analysts' consensus estimates of ($0.97) by ($0.04). Entrada Therapeutics had a negative net margin of 3,537.73% and a negative return on equity of 57.61%. The business had revenue of $0.90 million during the quarter, compared to analysts' expectations of $2.32 million. On average, analysts expect Entrada Therapeutics to post ($4.03) EPS for the current fiscal year and ($3.52) EPS for the next fiscal year.

Entrada Therapeutics Price Performance

Shares of TRDA stock opened at $4.84 on Thursday. The stock has a market capitalization of $188.46 million, a price-to-earnings ratio of -1.22 and a beta of -0.24. The company's fifty day simple moving average is $6.17 and its two-hundred day simple moving average is $8.78. Entrada Therapeutics has a 1 year low of $4.11 and a 1 year high of $16.45.

Insider Buying and Selling

In related news, major shareholder Bioventures 2014 L.P. Mpm sold 14,569 shares of the company's stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $7.06, for a total transaction of $102,857.14. Following the sale, the insider owned 4,318,348 shares of the company's stock, valued at approximately $30,487,536.88. This represents a 0.34% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Bioventures 2018 L.P. Mpm sold 28,837 shares of the stock in a transaction that occurred on Wednesday, September 9th. The stock was sold at an average price of $7.13, for a total transaction of $205,607.81. Following the completion of the sale, the insider owned 3,885,115 shares in the company, valued at $27,700,869.95. This represents a 0.74% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 717,449 shares of company stock worth $5,134,773 in the last ninety days. 9.49% of the stock is currently owned by insiders.

Analyst Ratings Changes

TRDA has been the subject of a number of analyst reports. Wall Street Zen upgraded Entrada Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, October 24th. UBS Group reiterated a "neutral" rating on shares of Entrada Therapeutics in a research note on Monday, October 19th. Roth Capital reissued a "buy" rating and set a $11.00 price objective on shares of Entrada Therapeutics in a report on Wednesday, August 12th. Weiss Ratings downgraded Entrada Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Friday, October 16th. Finally, HC Wainwright restated a "neutral" rating on shares of Entrada Therapeutics in a research note on Monday, October 19th. Four research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $17.75.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc NASDAQ: TRDA is a biotechnology company focused on developing therapeutics designed to enter cells and address diseases caused by abnormal or missing intracellular proteins. The company's approach is based on its Endosomal Escape Vehicle (EEV) platform, which is intended to deliver therapeutic payloads into target cells while helping them escape the endosome, a cellular compartment that can limit the effectiveness of some treatments.

Entrada is developing EEV-based medicines for serious diseases, particularly genetic and neuromuscular conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.